Compare Indonesia Energy Corporation Limited (INDO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Sanofi SA — how do they compare? Indonesia Energy Corporation Limited trades at $2.97 (market cap $45.55M), while Sanofi SA trades at $43.63 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2289.8× Indonesia Energy Corporation Limited's market cap, and Sanofi SA pays a 5.55% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| INDO | SNY | |
|---|---|---|
Market Cap | $45.55M | $104.30B |
Sector | Energy | Health |
52-Week High | $6.74 | $52.34 |
52-Week Low | $2.49 | $41.33 |
Enterprise Value | $40.92M | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.97, up 1.71% today, with a bullish technical signal supported by moving averages. The company reported a net loss of $5 million on $2 million revenue in 2025, resulting in negative profit margins. Recent news highlights operational progress with the commencement of drilling at the K-29 well in Indonesia. Analyst consensus is unanimously bullish with three buy ratings.
The outlook hinges on successful well development driving future revenue growth, but high valuation multiples and persistent losses pose significant risks. Investors face volatility from execution challenges in oil and gas exploration, though positive analyst sentiment suggests potential upside if operational milestones are met.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
